Vysis' PathVysion HER-2 Test Ships Dec. 18 At Premium To Dako's HercepTest
This article was originally published in The Gray Sheet
Vysis is betting that its fluorescence in situ hybridization (FISH)-based PathVysion HER-2 DNA probe kit justifies a significantly higher price than Dako's immunohistochemistry-based HercepTest.
You may also be interested in...
Genentech's Herceptin package insert to include use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test should address potential discrepancies in assay results compared with immunohistochemistry (IHC) tests, FDA's Oncologic Drugs Advisory Committee concluded
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.